ERBB2 and non-small cell lung carcinoma: Based on the findings of a multicenter, open-label, single-arm phase II clinical study evaluating the efficacy and safety of pyrotinib as a second-line or later treatment for advanced NSCLC with HER2 mutations, and given that the patient’s genetic testing revealed an ERBB2 exon 20 insertion mutation, The patient and her family ultimately chose oral pyrotinib monotherapy (400 mg once daily) as an individualized regimen, and treatment was initiated on September 26, 2022 (Figure 1B).